Name | Nocloprost |
---|---|
Synonyms |
(5Z,9β,11α,13E,15R)-9-Chloro-11,15-dihydroxy-16,16-dimethylprosta-5,13-dien-1-oic acid
(5Z,9b,11a,13E,15R)-9-Chloro-11,15-dihydroxy-16,16-dimethylprosta-5,13-dien-1-oic Acid Prosta-5,13-dien-1-oic acid, 9-chloro-11,15-dihydroxy-16,16-dimethyl-, (5Z,9β,11α,13E,15R)- (5Z,13E)-(9R,11R,15R)-9-chloro-11,15-dihydroxy-16,16-dimethyl-5,13-prostadienoic acid SH-475 (Z)-7-((1R,2R,3R,5R)-5-Chloro-3-hydroxy-2-((E)-(3R)-3-hydroxy-4,4-dimethyl-1-octenyl)cyclopentyl)-5-heptenoic acid (Z)-7-[(1R,2R,3R,5R)-5-chloro-2-hydroxy-2-[(E)-(3R)-3-hydroxy-4,4-dimethyl-1-octenyl]cyclopentyl]-5-heptenoic acid |
Description | Nocloprost, a prostaglandin E2 (PGE2) analog, is an orally active EP1- and EP3-receptor agonist. Nocloprost inhibits evoked [3H]ACh release. Nocloprost has gastroprotective and ulcer-healing properties. Nocloprost accelerates the healing of chronic gastric ulcerations and enhances mucosal growth in rats[1][2]. |
---|---|
Related Catalog | |
Target |
EP1 EP3 |
In Vivo | 诺氯前列素 (灌胃给药; 0.01-10 μg/kg) 在 100% 乙醇、酸化阿司匹林 (HY-14654)、酸化牛磺胆酸盐 (HY-N0545)、水浸或束缚应激前 30 分钟给药,会剂量依赖性地预防大鼠胃损伤的形成[1]。 诺氯前列素 (灌胃给药; 0.01-100 μg/kg) 不会影响胃酸分泌或肠道分泌,但会阻止胃十二指肠碱性分泌增加[1]。 诺氯前列素 (皮下给药) 显示出针对乙醇损伤的保护活性,但在十二指肠内应用时无效[1]。 Animal Model: 220-250 g rats[1] Dosage: 0.01-10 μg/kg Administration: Intragastrically; single dose Result: 30 min before 100% ethanol, acidified Aspirin (ASA), acidified Taurocholate, water immersion, or restraint stress dose dependently prevented the formation of gastric lesions, the ID50 values being 0.25, 0.58, 0.06 and 0.12 μg/kg in rats, respectively. |
References |
Density | 1.1g/cm3 |
---|---|
Boiling Point | 539.8ºC at 760 mmHg |
Molecular Formula | C22H37ClO4 |
Molecular Weight | 400.98000 |
Flash Point | 280.3ºC |
Exact Mass | 400.23800 |
PSA | 77.76000 |
LogP | 4.92550 |
Index of Refraction | 1.526 |